New stock news | Lingke Pharmaceuticals submit application to Hong Kong Stock Exchange

According to the disclosure on November 30 by the Hong Kong Stock Exchange, Lingke Pharmaceuticals (Zhejiang) Co., Ltd. (referred to as Lingke Pharmaceuticals) submitted an application to the main board of the Hong Kong Stock Exchange, with CITIC SEC and CICC International acting as joint sponsors. The prospectus shows that Lingke Pharmaceuticals is a leading pharmaceutical company based in China and oriented towards the global market, dedicated to developing new drugs for the treatment of tumors, immune and inflammatory diseases. The company was founded by senior experts in drug development, with team members accumulating rich experience in drug discovery for over decades. The company has shown outstanding efficiency in advancing its product development pipeline, with its core products LNK01001 and LNK01004 making significant progress. The company's first candidate product is expected to enter the preclinical stage, while the VAV1 program has already entered into the supportive research stage of new drug clinical trials.